LS CancerDiag gets the patent granted in Brazil for its innovative DiagMMR® test. The largest country in Latin America completes the already impressive patent portfolio of LS CancerDiag. Brazil brings the total count to 29
LS CancerDiag looks back on the year marked by the achievement of major milestones. 2019 started off with obtaining the CE mark for DiagMMR® as in vitro diagnostic medical device (IVD MD), enabling commercialization in
The last year of this decade has been a very successful one for LS CancerDiag, where many important milestones were achieved, and the basis was laid for strong growth over the coming years. To gear
We are excited to announce that Minttu Kansikas has been appointed as Chief Scientific Officer to lead the research efforts and laboratory functions. Congratulations! Minttu is a co-inventor and one of the leading scientists behind
Welcome! We have updated our website and hope you enjoy the new structure and features! This new section being one of them, and the twitter feed, being another. And there are many more to come!
LS CancerDiag joins the InvestHorizon Accelerator, we are delighted to have been accepted to the programme! InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding. The selected deep tech companies
Tonight our CSO Minttu Kansikas will be sharing the experience of taking promising research to the market. Join the panel discussion and networking event by @Helsinkithinkco #nordicmade #entrepreneurship #lscancerdiag #diagmmr #lynchsyndrome #endcancer
https://www.facebook.com/events/1405966726276075/
We are thrilled to announce that Brazil has granted LS CancerDiag the patent for its DiagMMR® innovation! This takes the count of our portfolio to 29 countries! #innovation #diagmmr #lscancerdiag #nordicmade #lynchsyndrome #endcancer
https://www.lscancerdiag.com/patent-granted-in-brazil/
